- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Mike Lattanzi: Precision Oncology Options and Increasing Rates of Prostate Cancer
Mike Lattanzi, MD, genitourinary medical oncologist, Texas Oncology, discusses the importance of keeping pace with precision oncology options as rates for prostate cancer increase.
Mike Lattanzi, MD, genitourinary medical oncologist at Texas Oncology, discusses the use of next-generation sequencing when treating an increasing number of patients with genitourinary diseases.
Transcript
Is payer coverage for genomic testing keeping pace with the precision oncology options in genitourinary disease?
I'm fortunate enough to be able to send next-generation sequencing on virtually all of my patients with metastatic disease. And I routinely send both tissue-based as well as liquid cell-free DNA next-generation sequencing for all patients with metastatic GU [genitourinary] cancers.
The most recent annual report on cancer statistics from the American Cancer Society showed a rise in prostate cancer after years of decline. What are your thoughts on why prostate cancer is increasing?
There's recently been an increase in the incidence of prostate cancer diagnoses as well as a trend toward later-stage diagnoses, which a lot of us feel is due to diminished screening during the COVID-19 pandemic. So, these data are just a reminder to always be screening patients in a guideline-appropriate fashion moving forward.
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
